Skip to main content
All lobbying filings

NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)

Lobbying for NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 16, 2025
Expenses
$50,000.00
What this organization spent lobbying with its own staff. Reported using B: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 5
  • Centers For Medicare and Medicaid Services (CMS)
  • Food & Drug Administration (FDA)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 2
 Lobbying activity 4
Health Issues

Rare Disease Initiatives. Affordable Care Act (ACA) Issues and Enhancements. Telehealth. Priority Review Voucher Reauthorization. Accelerated Approval. Newborn Screening.

Medicare/Medicaid

Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.

Pharmacy

Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Accelerated Approval. S.705: Innovation in Pediatric Drugs Act of 2025. H.R.1414: Camerons Law. Promising Pathways Act 2.0.

Budget/Appropriations

Appropriations impacting patients with rare diseases. National Institutes of Health (NIH) NCATS Appropriations.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem